<< Exhibitor
<< Press release
The 23rd China International In Vitro Diagnostics by CACLP was successfully held from 21-23 March 2026 in Xiamen, marking another milestone in the event’s continued expansion across China, Southeast Asia and the global market.
In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:
As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.
Amid the deepening implementation of the Healthy China 2030 strategy and the rapid convergence of a new global biotechnology revolution, in vitro diagnostics (IVD) has become more critical than ever.
The 11th China Experimental Medicine Conference, themed “Innovation Shaping the Future,” will be held from 21-22 March, 2026, in Xiamen.
As a vital link between innovation and clinical application, IVD distribution enterprises play an indispensable role in ensuring the efficient flow of diagnostic products and services.
Driven by rapid advances in healthcare technology, the IVD industry is entering a new era of innovation and growth. Enlightening Lab Med —— The 9th IVD Youth Entrepreneur Forum will take place on 21 March 2026 at the Xiamen International Expo Center.
As the global in vitro diagnostics (IVD) industry advances toward greater technological sophistication, intelligent automation, and broader clinical applications, the focus of innovation is shifting upstream. Beyond the development of cutting-edge instruments and assays, increasing attention is being placed on the foundational elements that enable performance and reliability—namely critical raw materials, core components, and robust standards systems. Breakthroughs in advanced materials, precision-engineered components, and cross-disciplinary integration are becoming central drivers of sustainable industry growth.
With less than one month remaining before its official opening, the 23rd China International In Vitro Diagnostics by CACLP, together with a series of academic conferences, industry forums, and business meetings, has entered its final countdown stage.
As the global in vitro diagnostics (IVD) industry undergoes rapid technological evolution and market restructuring, overseas expansion has become a key growth pathway for Chinese IVD companies.
<< Industry news
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
PureLab, part of PureHealth, has signed a Memorandum of Understanding (MoU) with Baynounah Gene Solutions to explore opportunities for collaboration across diagnostics innovation, synthetic biology, molecular sciences, and research and development initiatives in the UAE.
Seegene, a global molecular diagnostics company, announced the European launch of its new antimicrobial resistance (AMR) testing product, Allplex™ MDRO Assay, which is CE marked under the EU In Vitro Diagnostic Regulation (IVDR). The assay is designed to support the detection of multidrug-resistant organisms (MDROs) associated with healthcare-associated infections (HAIs).
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic (CDx) for TEPMETKO® (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. TEPMETKO received accelerated approval from the FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations (METex14).
Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the LIAISON PLEX Gastrointestinal Flex Assay, a fully customizable syndromic testing panel capable of detecting a market-leading 24 gastrointestinal pathogen targets. The new panel expands Diasorin’s growing LIAISON PLEX assay portfolio, which also includes a customizable respiratory assay and three blood culture panels.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assessing a 100X wider genomic footprint than the previously approved Guardant360 CDx to deliver comprehensive tumor profiling results. The seven previously U.S. FDA-approved companion diagnostic indications for Guardant360 CDx transfer to the new test with the FDA approval of Guardant360 Liquid CDx.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.
At present, domestic blood typing reagent-related products already covered ABO blood typing, test of Rh and other irregular antibodies, and anti-human globulin test.
AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets, a first in the region. This landmark collaboration aims to accelerate the adoption of AI-powered digital and computational pathology through educational and training initiatives and improve biomarker testing in breast and lung cancer.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
<< Video showcase
Talk with Prof. Leslie Lam at CACLP 2026
Talk with Prof. Vittorio Sambri at CACLP 2026
Talk with Prof. Sergio Bernardini at CACLP 2026
Talk with Prof. Rajiv Erasmus at CACLP 2026
Talk with Prof. Aldo Tomasi at CACLP 2026
Talk with Yinan Tang at CACLP 2026
Talk with Shaoting Zhang at CACLP 2026
Talk with Huai Chen at CACLP 2026
Talk with CHIA Wai Kian at CACLP 2026
Talk with Rahul AGARWAL at CACLP 2026
Talk with Jag Grewal at CACLP 2026
CACLP 2026 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 13th China IVD Industry Development Conference & The 11th China Experimental Medicine Conference
CACLP International Night 2026
The 1st Global IVD Innovation Summit
Go Global: China IVD International Forum 2026
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
<< Download centre
CACLP 2026 Floor Plan
CACLP 2026 Full Schedule
CACLP 2026 Exhibitor Manual
CACLP 2025 Post-show Report
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
